Barclays
BEAM icon

Barclays’s Beam Therapeutics BEAM Stock Holding History

Barclays’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$735K – 5275
2024
Q3 		$735K Buy
+30,000
New +$775K ﹤0.01% 3551
2024
Q2 		– Sell
-47,000
Closed -$1.55M – 4881
2024
Q1 		$1.55M Buy
+47,000
New +$1.46M ﹤0.01% 2775

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Barclays's BEAM Position: Q1 2026 in Review

Barclays reduced its Beam Therapeutics (BEAM) stake by 85% in Q1 2026, selling an estimated $7.73M and leaving 47,638 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

Barclays first reported a position in BEAM in Q1 2022 and has held it in 17 quarters since. The position peaked at $11.6M in Q2 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Barclays held 47,638 shares of Beam Therapeutics worth $1.14M as of Q1 2026.
  • Barclays sold 278,540 Beam Therapeutics shares in Q1 2026, an estimated $7.73M.
  • Beam Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2679 holding.
  • Barclays first reported a position in Beam Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Beam Therapeutics position peaked at $11.6M in Q2 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.